# A Study of YL202 in Selected Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06107686/  
OnCo record `nct06107686` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of YL202 should be intravenously infused in non-small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL202 in Selected Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06107686 by MediLink Therapeutics (Suzhou) Co., Ltd., with 200 participants planned, started 2023-12-15 and due to reach its primary completion in 2026-11. Interventions recorded: YL202 should be intravenously infused.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06107686
- Phase: 2
- Setting: A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT06107686: https://clinicaltrials.gov/study/NCT06107686

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06107686.json